Medicaments for the treatment of non-constipated female irritable bowel syndrome
AssigneeGlaxo Wellcome Inc.
InventorsAllen Wayne Mangel, Allison Ruth Northcutt
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.
Claims9
A method of treatment of nonconstipated female IBS which comprises administering an effective amount of a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof.
A method of treatment of nonconstipated female IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative.
A method of treatment of diarrhea-predominant female IBS which comprises administering an effective amount of a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof.
A method of treatment of diarrhea-predominant female IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative thereof.
A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof.
A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative thereof.
Dependencies are inferred from the claim text.